You are here:Home-Inhibitors & Agonists-Metabolic Enzyme/Protease-Acetyl-CoA Carboxylase (ACC)

Request The Product List ofAcetyl-CoA Carboxylase (ACC) Acetyl-CoA Carboxylase (ACC)

Cat. No. Product Name CAS No. Information
PC-61377

Firsocostat

1434635-54-7

Firsocostat (ND-630, NDI-010976, GS-0976) is a highly potent, selective inhibitor of acetyl-CoA carboxylase (ACC) with IC50 of 2.1 and 6.1 nM for isozymes ACC1 and ACC2, respectively; displays no activity against 101 enzymes, receptors, growth factors, transporters, and ion channels at 10 uM; reduces hepatic steatosis, improves insulin sensitivity, reduces weight gain without affecting food intake, and favorably affects dyslipidemia in DIO mice.

Steatohepatitis

Phase 2 Clinical

PC-42306

TOFA

54857-86-2

TOFA (RMI14514, MDL14514) is an indirect, allosteric inhibitor of Acetyl-CoA carboxylase-α (ACCA) and fatty acid synthesis; converted to TOFyl-CoA, exerts an allosteric inhibition on ACCA; lowers blood lipids and inhibits fatty acid synthesis with minimal effects on liver weight and liver fat content; also induces human cancer cell apoptosis through disturbing their fatty acid synthesis.

PC-63466

PF-05175157

1301214-47-0 PF-05175157 (PF-5175157) is a potennt Acetyl-CoA carboxylase (ACC) inhibitor with IC50 of 27 and 33 nM for hAAC1 and hACC2, respectively; shows concentration-dependent reductions in both skeletal muscle and liver malonyl-CoA with EC50 of 870 and 540 nM after 1 h following an acute oral dose in rats; demonstrates significant potential for the treatment of type 2 diabetes mellitus (T2DM).

Diabetes

Phase 2 Discontinued

PC-61206

MK-4074 sodium salt

1039758-18-3 MK-4074 is a potent, liver-specific, orally active inhibitor of acetyl-CoA carboxylase ACC1 and ACC2 with IC50 of ~3 nM; lowers lipogenesis, increases ketones and reduces liver triglycerides, increases plasma triglycerides in mice; significantly decreases de novo lipogenesis (DNL) in a dose-dependent manner with ID50 of 0.9 mg/kg in models of obesity, type 2 diabetes and fatty liver.

Steatohepatitis

Phase 1 Clinical

PC-61204

MK-4074

1039758-22-9 MK-4074 is a potent, liver-specific, orally active inhibitor of acetyl-CoA carboxylase ACC1 and ACC2 with IC50 of ~3 nM; lowers lipogenesis, increases ketones and reduces liver triglycerides, increases plasma triglycerides in mice; significantly decreases de novo lipogenesis (DNL) in a dose-dependent manner with ID50 of 0.9 mg/kg in models of obesity, type 2 diabetes and fatty liver.

Steatohepatitis

Phase 1 Clinical

Request The Product List

* Indicates a Required FieldYour information is safe with us.

  • *Product List:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Country:
  • Additional Information:
Contact Us sales@probechem.com